EPO and anemia (phenotype): During the follow-up period (median 959 days, range: 7-3595 days), 84 (48%) patients developed anemia (new anemia in 48 patients, further development of anemia in 32 patients, initiation of iron supplementation in 2 patients and initiation of EPO in 2 patients).